Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
731 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer(SENTINEL) | terminated | Phase 1 | 10 | GSO Global Clinical Research BVOTHER | 2 | Apr 8, 2022 | clinicaltrials |
| NCT02978755 | First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers | completed | Phase 1 | 78 | GamaMabs PharmaINDUSTRY | 3 | Apr 6, 2022 |
| NCT02410512 | A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 610 | Genentech, Inc.INDUSTRY | 7 | Apr 1, 2022 | clinicaltrials |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | completed | Phase 1 | 283 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 29, 2022 | clinicaltrials |
| NCT03579628 | AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors(DRIIV-1) | completed | Phase 1 | 33 | Valerio TherapeuticsINDUSTRY | 2 | Mar 24, 2022 | clinicaltrials |
| NCT04991948 | Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | recruiting | Phase 1 | 34 | Celyad Oncology SAINDUSTRY | 2 | Mar 9, 2022 | clinicaltrials |
| NCT03551782 | A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 33 | Janssen Research & Development, LLCINDUSTRY | 7 | Feb 25, 2022 | clinicaltrials |
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 / Phase 2 | 490 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 10, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT02705963 | A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors | completed | Phase 1 | 19 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 9, 2022 | clinicaltrials |
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 138 | Pharmacyclics LLC.INDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT05177640 | Biodistribution and Dosimetry of 99mTc-Duramycin(PicTURE) | completed | Phase 1 | 6 | University Hospital, AntwerpOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT01772004 | Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | completed | Phase 1 | 1,756 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 9 | Dec 20, 2021 | clinicaltrials |
| NCT02686346 | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE(BV-ICE) | completed | Phase 1 / Phase 2 | 53 | The Lymphoma Academic Research OrganisationOTHER | 2 | Dec 7, 2021 | clinicaltrials |
| NCT02741388 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP(SELINDA) | completed | Phase 1 | 39 | The Lymphoma Academic Research OrganisationOTHER | 2 | Dec 7, 2021 | clinicaltrials |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | terminated | Phase 1 / Phase 2 | 10 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT03661632 | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 27 | Bristol-Myers SquibbINDUSTRY | 3 | Nov 8, 2021 | clinicaltrials |
| NCT01750918 | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 166 | Novartis PharmaceuticalsINDUSTRY | 8 | Oct 29, 2021 | clinicaltrials |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma(DESPARTH) | terminated | Phase 1 | 2 | University Hospital, GhentOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03752177 | A Study of LY3415244 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT04882163 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 8 | Oct 5, 2021 | clinicaltrials |
| NCT03403725 | MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study(CD205SHUTTLE) | terminated | Phase 1 | 28 | Menarini GroupINDUSTRY | 4 | Sep 28, 2021 | clinicaltrials |
| NCT02626000 | Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)(MASTERKEY232) | completed | Phase 1 | 36 | AmgenINDUSTRY | 11 | Sep 8, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT03898791 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | completed | Phase 1 | 48 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 5, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT03394937 | Safety of Intranodal ECI-006 in Melanoma Patients | terminated | Phase 1 | 21 | eTheRNA immunotherapiesINDUSTRY | 2 | Jun 21, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT03411161 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Institut de Recherches Internationales ServierOTHER | 4 | May 25, 2021 | clinicaltrials |
| NCT01693562 | A Phase 1/2 Study to Evaluate MEDI4736 | completed | Phase 1 / Phase 2 | 1,022 | MedImmune LLCINDUSTRY | 9 | May 13, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT03009214 | A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours | completed | Phase 1 | 55 | amcure GmbHINDUSTRY | 2 | May 10, 2021 | clinicaltrials |
| NCT03466320 | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2(DEPLETHINK) | completed | Phase 1 / Phase 2 | 21 | Celyad Oncology SAINDUSTRY | 2 | May 4, 2021 | clinicaltrials |
| NCT03283202 | Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors | completed | Phase 1 | 35 | CelgeneINDUSTRY | 4 | Apr 29, 2021 | clinicaltrials |
| NCT03754179 | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma(COMBI-R2) | unknown | Phase 1 / Phase 2 | 63 | Universitair Ziekenhuis BrusselOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01857193 | Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | completed | Phase 1 | 132 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 13, 2021 | clinicaltrials |
| NCT01251640 | Combination With Gemcitabine in Advanced Pancreatic Cancer(BAGPAC) | completed | Phase 1 / Phase 2 | 90 | BayerINDUSTRY | 9 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT04082182 | MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer(MIDRIX4-LUNG) | unknown | Phase 1 | 7 | University Hospital, GhentOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT01927341 | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | completed | Phase 1 / Phase 2 | 53 | PfizerINDUSTRY | 7 | Feb 18, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT03747744 | Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)(myDCTV) | unknown | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT00426530 | Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | completed | Phase 1 | 50 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 21, 2020 | clinicaltrials |
| NCT00434174 | Safety of Everolimus and Pemetrexed in Lung Cancer Patients | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT00446082 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | completed | Phase 1 | 85 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT01443481 | Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials